Exploring the 2008 pharmaceutical pipeline
Three newly published Pharma Matters reports use market intelligence and competitive analysis to explore various aspects of the 2008 pharmaceutical pipeline.
The Ones to Watch – Our latest quarterly review of the phase changes in the pharmaceutical pipeline reveals the top five most promising drugs launched or receiving approval in quarter one 2008. These include Tibotec's Intelence™, targeted at HIV-1 infection, and Ionsys™, being developed by ALZA for acute pain.
Movers and Shakers – This quarterly report analyses the U.S. generics industry. In quarter one 2008 this analysis uncovered observations that
- The U.S. generics market is remarkably robust but will be hit by the current downturn in drugs innovation, which will translate into a decline in off-patent drugs from 2012
- 'Super Generic' companies such as Teva and Mylan now dominate the generics market and will be the best placed to survive any future downturns
- Final approvals were issued on 134 'A'-rated ANDAs, up from 108 the quarter before
Who is Making the Biggest Splash? – This report reviews scientific literature on drugs and therapies, assessing the quantity and quality of the materials published by pharmaceutical companies, research institutions and other non-commercial bodies. The five organizations with the biggest impact from January to March 2008 were Eli Lilly, sanofi-aventis, Novartis, Bristol-Myers Squibb and GlaxoSmithKline.
Stay up to date with Pharma Matters
Subscribe to receive the latest and future editions of these reports free every quarter
Additional information
Subscribe to receive the latest and future editions of these reports free every quarterWas this article useful?
Register now for KnowledgeLink, our customizable email newsletter that delivers expert insight on:
- Global innovation
- Information professional development
- Intellectual property
- Pharmaceutical knowledge
- Scientific research